Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry

待确认 10 由 Zenith 发布于 2026/7/28 23:27:14

DOI:10.1080/1354750x.2024.2342016
作者：Alexander L. Reese-Petersen, Helene W. Breisnes, Daniel Gabor, Sarah R. R?nnow, Bruna Manoel, Mayuur Bajaj, Claus S. von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A. Karsdal
文献类型：期刊论文
补充材料：只需要正文

Taylor & Francis

Abstract：IntroductionThere is an urgent, persistent, need for better biomarkers in clinical drug development. More informative biomarkers can increase the likelihood of drug advancement or approval,

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

1天前

太白伊丽莎白

8f9bf8b48adb11f1b64134735aa3bc31.pdf

1天前

Book学术机器人

2026/7/28 23:27:15 未找到该文献，机器人已退出，请等待人工下载

2026/7/28 23:27:14 Book学术AI机器人收到请求，开始寻找文献

2026/7/28 23:27:14 已向机器人发送请求

1天前

Zenith 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities.